Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Gilead Sciences Inc (GILD)

Gilead Sciences Inc (GILD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 192,640,400
  • Shares Outstanding, K 1,240,680
  • Annual Sales, $ 29,443 M
  • Annual Income, $ 8,510 M
  • EBIT $ 10,023 M
  • EBITDA $ 12,790 M
  • 60-Month Beta 0.36
  • Price/Sales 6.53
  • Price/Cash Flow 19.19
  • Price/Book 8.50

Options Overview Details

View History
  • Implied Volatility 27.55% (-1.73%)
  • Historical Volatility 32.81%
  • IV Percentile 33%
  • IV Rank 21.41%
  • IV High 49.97% on 04/08/25
  • IV Low 21.43% on 12/10/25
  • Expected Move (DTE 2) 2.40 (1.57%)
  • Put/Call Vol Ratio 2.82
  • Today's Volume 20,088
  • Volume Avg (30-Day) 13,629
  • Put/Call OI Ratio 0.65
  • Today's Open Interest 172,256
  • Open Int (30-Day) 153,944
  • Expected Range 150.34 to 155.14

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 30 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 1.85
  • Number of Estimates 9
  • High Estimate 2.00
  • Low Estimate 1.69
  • Prior Year 1.81
  • Growth Rate Est. (year over year) +2.21%

Price Performance

See More
Period Period Low Period High Performance
1-Month
122.28 +24.91%
on 01/20/26
157.29 -2.89%
on 02/11/26
+27.83 (+22.28%)
since 01/16/26
3-Month
116.88 +30.68%
on 01/05/26
157.29 -2.89%
on 02/11/26
+25.56 (+20.10%)
since 11/18/25
52-Week
93.37 +63.59%
on 04/25/25
157.29 -2.89%
on 02/11/26
+47.49 (+45.12%)
since 02/18/25

Most Recent Stories

More News
Gilead to Present New HIV Treatment and Prevention Data at CROI 2026, With a Focus on Expanding Options

– Pivotal Phase 3 Findings Support the Potential of a Novel Single-Tablet Combination of Bictegravir and Lenacapavir for HIV Treatment – ...

GILD : 152.74 (-1.63%)
5 Insightful Analyst Questions From Gilead Sciences’s Q4 Earnings Call

5 Insightful Analyst Questions From Gilead Sciences’s Q4 Earnings Call

GILD : 152.74 (-1.63%)
3 Hyped Up Stocks We Steer Clear Of

3 Hyped Up Stocks We Steer Clear Of

SITE : 152.39 (-0.74%)
TXT : 100.25 (+0.55%)
GILD : 152.74 (-1.63%)
Cencora, Azenta, The Pennant Group, LifeStance Health Group, and Gilead Sciences Shares Are Soaring, What You Need To Know

Cencora, Azenta, The Pennant Group, LifeStance Health Group, and Gilead Sciences Shares Are Soaring, What You Need To Know

PNTG : 32.65 (+2.51%)
COR : 360.23 (+0.07%)
LFST : 7.13 (+1.28%)
AZTA : 29.83 (+4.16%)
GILD : 152.74 (-1.63%)
3 Overrated Stocks That Concern Us

3 Overrated Stocks That Concern Us

VSH : 19.40 (+3.80%)
PANL : 8.93 (+4.20%)
GILD : 152.74 (-1.63%)
Stocks Settle Mixed as Fed Rate Cut Chances Slip

The S&P 500 Index ($SPX ) (SPY ) closed unchanged on Wednesday, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down -0.13%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.29%. March E-mini...

MSTR : 125.20 (-2.70%)
LSCC : 97.23 (-0.28%)
ADI : 346.37 (+2.63%)
GLXY : 21.73 (+2.02%)
COIN : 164.05 (-1.19%)
STX : 424.14 (+1.97%)
WDC : 296.56 (+4.38%)
VRT : 243.21 (-0.13%)
^BTCUSD : 66,492.05 (+0.19%)
SPY : 686.29 (+0.50%)
ADSK : 229.74 (+1.96%)
MU : 420.95 (+5.30%)
Stocks Turn Mixed as Software Stocks Slide

The S&P 500 Index ($SPX ) (SPY ) today is down -0.02%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.19%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.10%. March E-mini S&P futures (ESH26...

AMAT : 369.30 (+2.83%)
MAT : 17.28 (+2.61%)
INTU : 389.57 (+2.74%)
LSCC : 97.23 (-0.28%)
ADI : 346.37 (+2.63%)
DDOG : 121.78 (-0.64%)
RPD : 7.14 (+0.99%)
TXN : 223.32 (-1.05%)
$IUXX : 24,898.87 (+0.80%)
ZNH26 : 112-300 (-0.01%)
MSFT : 399.60 (+0.69%)
TDC : 32.81 (+0.64%)
GILD Q4 Deep Dive: HIV Prevention and Oncology Advances Drive Mixed Outlook

GILD Q4 Deep Dive: HIV Prevention and Oncology Advances Drive Mixed Outlook

GILD : 152.74 (-1.63%)
Gilead Sciences’s (NASDAQ:GILD) Q4 CY2025 Sales Beat Estimates

Gilead Sciences’s (NASDAQ:GILD) Q4 CY2025 Sales Beat Estimates

GILD : 152.74 (-1.63%)
Gilead: Q4 Earnings Snapshot

Gilead: Q4 Earnings Snapshot

GILD : 152.74 (-1.63%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 70%. The market has dropped from overbought territory. Beware of a potential mean reversion.

See More Share

Business Summary

Gilead Sciences is a pioneer in developing drugs for the treatment of human immunodeficiency virus, liver diseases, hematology/oncology diseases and inflammation/respiratory diseases. The company has a strong HIV franchise with key HIV/AIDS therapies like tenofovir alafenamide based products - Genvoya,...

See More

Key Turning Points

3rd Resistance Point 158.68
2nd Resistance Point 157.35
1st Resistance Point 155.04
Last Price 152.74
1st Support Level 151.40
2nd Support Level 150.07
3rd Support Level 147.76

See More

52-Week High 157.29
Last Price 152.74
Fibonacci 61.8% 132.87
Fibonacci 50% 125.33
Fibonacci 38.2% 117.79
52-Week Low 93.37

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar